<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02773394</url>
  </required_header>
  <id_info>
    <org_study_id>CR107066</org_study_id>
    <secondary_id>TMC435HPC4013</secondary_id>
    <nct_id>NCT02773394</nct_id>
  </id_info>
  <brief_title>Study to Describe the Actual Situation of Hepatitis C Treatment in Brazil</brief_title>
  <acronym>PICTURE</acronym>
  <official_title>Protocol to Describe the Actual Situation of Hepatitis C Treatment in Brazil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen-Cilag Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen-Cilag Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to describe: 1) the clinical profile, past and current management
      of participants with hepatitis C in Brazil reference centers; 2) the current situation about
      demographics characteristics, liver disease progression and clinical outcomes in Brazilian
      Hepatitis C virus (HCV) participants naive, in treatment and previously exposed to antiviral
      treatment without sustained virological response (SVR).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational, non-interventional, cross-sectional, multicenter study to describe
      demographic characteristics, treatment performed and clinical outcomes of Brazilian
      participants with HCV chronic infection in about 12 Brazilian reference centers. It will
      expect that approximately 2000 participants will be enrolled in the study. Analysis set will
      consist of participants with HCV chronic infection who are registered at the Brazilian
      reference centers and meet all the inclusion criteria and have sufficient information to
      identify the diagnosis of chronic HCV infection with identification of genotype. The study
      related data will be collected from the medical records in the predesigned electronic Case
      Report Form (eCRF).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 12, 2016</start_date>
  <completion_date type="Actual">November 30, 2016</completion_date>
  <primary_completion_date type="Actual">November 30, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with chronic hepatitis C infection</measure>
    <time_frame>Day 1</time_frame>
    <description>Data will be collected through medical records of the participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Date of last visit</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with chronic hepatitis C infection Reported Based on City and States</measure>
    <time_frame>Day 1</time_frame>
    <description>Data will be collected through medical records of the participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with chronic hepatitis C infection Based on precedence</measure>
    <time_frame>Day 1</time_frame>
    <description>Data will be collected through medical records of the participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Age of Participants with chronic hepatitis C infection</measure>
    <time_frame>Day 1</time_frame>
    <description>Data will be collected through medical records of the participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Males and Females with chronic hepatitis C infection</measure>
    <time_frame>Day 1</time_frame>
    <description>Data will be collected through medical records of the participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with chronic hepatitis C infection Reported Based on Race</measure>
    <time_frame>Day 1</time_frame>
    <description>Data will be collected through medical records of the participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mode of Hepatitis C virus (HCV) transmission</measure>
    <time_frame>Day 1</time_frame>
    <description>Data will be collected through medical records of the participants. Mode of HCV transmission route (unsafe injections, hemodialysis, infection drug use, blood transfusion, sexual transmission, vertical transmission, unknown, other) will be analysed by number of participants infected with HCV per transmission route.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of diagnosis of chronic hepatitis C infection</measure>
    <time_frame>Day 1</time_frame>
    <description>Data will be collected through medical records of the participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HCV genotype and subtype</measure>
    <time_frame>Day 1</time_frame>
    <description>Data will be collected through medical records of the participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver characteristics: Number of Participants with extra hepatic manifestations</measure>
    <time_frame>Day 1</time_frame>
    <description>Data will be collected through medical records of the participants. Presence or absence of extra hepatic manifestations (cryoglobulinemia, lymphoma, Sjogren syndrome, glomerulopathy, Porphyria cutanea tarda, liquen planus, diabetes mellitus, thyroiditis, arthralgia).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver characteristics: Number of Participants with presence of comorbidities</measure>
    <time_frame>Day 1</time_frame>
    <description>Data will be collected through medical records of the participants. Presence of comorbidities (amount of alcohol ingestion, metabolic syndrome, hepatocellular carcinoma, organ transplantation, diabetes, immunodeficiency, renal insufficiency and dialysis, use of drugs) will be collected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver characteristics: Model for End-Stage Liver Disease (MELD) Score and Child Pugh score</measure>
    <time_frame>Day 1</time_frame>
    <description>MELD is a scoring system for assessing the severity of chronic liver disease. Child-Pugh classification assesses the prognosis of chronic liver disease by 5 clinical measures, scored 1-3 each (most severe derangement=3). Score range: 5 (best prognosis) to 15 (worst prognosis).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver characteristics: Number of Participants with Fibrosis based on Fibroscan</measure>
    <time_frame>Day 1</time_frame>
    <description>Data will be collected through medical records of the participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Coinfections</measure>
    <time_frame>Day 1</time_frame>
    <description>Data will be collected through medical records of the participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HCV treatment status on Day 1: Percentage of participants receiving antiviral treatment</measure>
    <time_frame>Day 1</time_frame>
    <description>Data will be collected through medical records of the participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HCV treatment status on Day 1: Causes of interruption in treatment</measure>
    <time_frame>Day 1</time_frame>
    <description>Data will be collected through medical records of the participants. Causes of interruption to antiviral therapy will be collected and reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HCV treatment status on Day 1: Number of participants treated without Sustained Virological Response (SVR)</measure>
    <time_frame>Day 1</time_frame>
    <description>Data will be collected through medical records of the participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment regimen</measure>
    <time_frame>Day 1</time_frame>
    <description>The drugs used and time of treatment will be collected through medical records of the participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Adverse Events (AEs)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1649</enrollment>
  <condition>Hepatitis C Virus</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Brazilian participants with Hepatitis C virus (HCV) chronic infection who are registered at the Brazilian reference centers and meet all the inclusion criteria and have sufficient information to identify the diagnosis of chronic HCV infection with identification of genotype.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Analysis set will consist of participants with Hepatitis C virus (HCV) chronic infection
        who are registered at the Brazilian reference centers and meet all the inclusion criteria
        and have sufficient information to identify the diagnosis of chronic HCV infection with
        identification of genotype.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with diagnosis confirmed with Hepatitis C infection being followed into
             the reference centers

          -  There is no restriction on fibrosis stage or clinical liver disease

          -  There is no restriction for comorbities or coinfections

          -  Diagnosis of chronic HCV infection detected by anti-HCV (ELISA assays), HCV
             Ribonucleic acid (RNA) (polymerase chain reaction [PCR] reaction) with identification
             of genotype

        Exclusion Criteria:

          -  Male or female participant with age greater than or equal to 18 years

          -  participating in another interventional clinical trial

          -  Treated participants who achieved sustained Virological Response (SVR)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen-Cilag Ltd. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen-Cilag Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Goi√¢nia</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Velho</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Recife</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rio Branco</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rio De Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salvador</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2016</study_first_submitted>
  <study_first_submitted_qc>May 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2016</study_first_posted>
  <last_update_submitted>May 5, 2017</last_update_submitted>
  <last_update_submitted_qc>May 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C Virus</keyword>
  <keyword>Observational</keyword>
  <keyword>Brazil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

